Vanutide cridificar

Drug Profile

Vanutide cridificar

Alternative Names: AAC 001; ACC-001; Active beta-amyloid immunotherapeutic conjugate; Aβ immunotherapeutic conjugate; CRM 197; Peptide-CRM Conjugate; PF-05236806; PF-5236806

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Elan Corporation; Wyeth
  • Developer JANSSEN Alzheimer Immunotherapy; Pfizer
  • Class Alzheimer vaccines; Antidementias; Carrier proteins; Immunoconjugates; Peptide fragments
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 01 Mar 2016 Pfizer terminates a phase II long-term extension trial in Alzheimer's disease in USA (NCT00960531)
  • 01 Feb 2014 Pfizer and JANSSEN Alzheimer Immunotherapy complete a phase II trial in Alzheimer's disease in USA (NCT01227564)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top